Published Date: 15 Mar 2023
A world first: A research team from Tel Aviv University and the Israel Institute of Biology has developed an anti-mRNA drug that is 100% effective against a single type of virus.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
2.
According to a study, white Americans are overdiagnosing melanoma at an alarming rate.
3.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
4.
Why breast cancer survivors don't take their medicine, and what can be done about it.
5.
Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'
1.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
2.
Oncologic Emergencies: Diagnosis and Treatment
3.
Different Types of Blood Dyscrasias
4.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
5.
Case Study: Genomic Medicine in Precision Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation